<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04761653</url>
  </required_header>
  <id_info>
    <org_study_id>2021PI015</org_study_id>
    <nct_id>NCT04761653</nct_id>
  </id_info>
  <brief_title>Study of the Inflammatory Microenvironment in Atypical Meningiomas</brief_title>
  <official_title>Prognostic Impact of the Inflammatory Microenvironment in Atypical Meningiomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atypical meningiomas represent 15% of meningiomas. They present a high rate of recurrence,&#xD;
      and therapeutic strategies are limited. There is a need for novel treatment strategies, such&#xD;
      as immuotherapy.&#xD;
&#xD;
      This is a retrospective study including 84 patients with primary diagnosis of atypical&#xD;
      meningiomas. The presence of T cells (CD4, CD8, Treg and memory T cells) and mature dendritic&#xD;
      cells will be quantified on whole tissue sections stained by immunohistochemistry (CD4, CD8,&#xD;
      FOXP3, CD45RO and CD208).&#xD;
&#xD;
      This could allow us to identify novel biomarkers for survival, and facilitate the selection&#xD;
      of patients who may benefit from immunotherapeutic modalities.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>2-21 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2-21 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Atypical Meningioma</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      FFPE tissue block&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients operated for a cerebral tumor, with primary diagnosis of atypical meningioma&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  primary diagnosis of atypical meningioma&#xD;
&#xD;
          -  surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Guillaume GAUCHOTTE</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume GAUCHOTTE, PU-PH</last_name>
      <phone>0033 3 83 65 60 17</phone>
      <email>guillaume.gauchotte@univ-lorraine.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 16, 2021</study_first_submitted>
  <study_first_submitted_qc>February 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>February 16, 2021</last_update_submitted>
  <last_update_submitted_qc>February 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Central Hospital, Nancy, France</investigator_affiliation>
    <investigator_full_name>Guillaume GAUCHOTTE</investigator_full_name>
    <investigator_title>PU PH</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

